Login / Signup

Adverse events and humoral response after two doses of severe acute respiratory coronavirus virus 2 (SARS-CoV-2) mRNA vaccine in the hospital personnel of a cardiopulmonary tertiary-care center.

Erica De VitaFrancesco SbranaFilippo QuattroneBeatrice Dal PinoMonica MegaroRoberta LombardiConcetta PronteraClaudio PassinoMaurizio Petrillo
Published in: Infection control and hospital epidemiology (2021)
Keyphrases
  • sars cov
  • tertiary care
  • immune response
  • respiratory syndrome coronavirus
  • healthcare
  • acute care
  • binding protein
  • adverse drug
  • emergency department
  • coronavirus disease
  • disease virus